47 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
26 Sep 22
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
9:00am
) administration options are currently limited to intravenous, generally requiring administration in the emergency department, or nasal spray administration
8-K
4iiq44wf jvb
15 Feb 22
Other Events
4:15pm
424B5
6l13c ocy3c
17 Dec 21
Prospectus supplement for primary offering
6:13am
DEFA14A
EX-10.1
41itu 9fikk5w
15 Dec 21
Additional proxy soliciting materials
5:27pm
8-K
EX-10.1
iuc90a5q
15 Dec 21
Pulmatrix Announces $6.75 Million Registered Direct Offering
5:27pm
8-K
k6qjithrg72uv6znjq
23 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
EX-10.1
zfarkdf1zq8ihey
16 Feb 21
Entry into a Material Definitive Agreement
4:30pm
424B5
0ae1u ddoplll
16 Feb 21
Prospectus supplement for primary offering
7:30am
424B5
x024xmaj
20 Apr 20
Prospectus supplement for primary offering
6:22am
8-K
EX-10.1
1cjzi9z
16 Apr 20
Pulmatrix Announces $8.0 Million Registered Direct Offering
5:27pm
8-K
EX-10.1
j2wmxbno
15 Apr 20
Entry into a Material Definitive Agreement
5:02pm